Rigel Pharmaceuticals, Inc.

RIGL· NASDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences

$37.43+1.68%

2026-08-03

Financials

Valuation Metrics

Rigel Pharmaceuticals, Inc.'s Market Cap is $693M. At end of 2025 it was $770M. Ranked #2665 of 3,112 in US market (top 86%), #1130 of 1,445 on NASDAQ (top 78%), #212 of 269 in Pharmaceuticals, Biotechnology & Life Sciences (top 79%) by Market Cap.

Investment Metrics(as of 2026-08-03)

Metric	Value	Rank
Size
Market Cap	$693M	US#2,665/3,112 Sec#212/269
Revenue	$300M	US#2,552/3,112 Sec#97/269
Net Income	$364M	US#975/3,112 Sec#36/269
Total Assets	$505M	US#2,738/3,112 Sec#155/269
Net Assets	$400M	US#2,406/3,112 Sec#132/269
Value
P/E	1.90x	US#9/3,112 Sec#1/269
P/B	1.73x	US#1,008/3,112 Sec#46/269
P/S	2.31x	US#1,413/3,112 Sec#38/269
EV/EBITDA	5.44x	US#190/3,112 Sec#13/269
FCF Yield	11.45%	US#398/3,112 Sec#16/269
Profitability
ROE	91.08%	US#42/3,112 Sec#5/269
ROA	72.18%	US#2/3,112 Sec#1/269
Op. Margin	41.56%	US#214/3,112 Sec#12/269
Revenue Growth	10.28%	US#1,284/3,112 Sec#93/269
Earnings Growth	-24.39%	US#1,703/3,112 Sec#52/269
Financial Health
Debt Ratio	26.18%	US#284/3,112 Sec#93/269
Total Debt	$46M	US#2,566/3,112 Sec#152/269
FCF	$79M	US#1,769/3,112 Sec#65/269
Cash	$24M	US#2,818/3,112 Sec#256/269
Current Ratio	2.62x	US#952/3,112 Sec#208/269
Net Debt/EBITDA	0.16x	US#698/3,112 Sec#39/269
Performance
1Y Return	70.84%	US#539/3,112 Sec#105/269
1M Return	-3.33%	US#2,058/3,112 Sec#107/269
From 52W High	-28.35%	US#2,098/3,112 Sec#155/269
1Y MDD	-50.08%	US#2,404/3,112 Sec#185/269
Trading
Volume	179,709 shares	US#2,717/3,112 Sec#254/269
Trading Value	$7M	US#2,540/3,112 Sec#206/269
Per Share
EPS	$20.40	US#72/3,112 Sec#5/269
BPS	$21.76	US#1,121/3,112 Sec#27/269